Adagrasib (MRTX849) is another KRAS G12C inhibitor that has shown activity in previously treated NSCLC and CRC patients in the phase I/Ib KRYSTAL-1 study [26] and is being studied in combination with cetuximab. This evidence concerns the gene KRAS and colorectal carcinoma.